Coeptis Therapeutics Warrants
COEPW
COEPW was delisted on the 24th of April, 2026.
3 hedge funds and large institutions have $2.73K invested in Coeptis Therapeutics Warrants in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 7 closing their positions.
1.48% less ownership
Funds ownership: 3.91% → 2.43% (-1.5%)
56% less capital invested
Capital invested by funds: $6.28K → $2.73K (-$3.54K)
70% less funds holding
Funds holding: 10 → 3 (-7)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Trading
New York
|
-$927 |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$537 |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$279 |
| 4 |
TSS
Two Sigma Securities
New York
|
-$237 |
| 5 |
CS
Clear Street
New York
|
-$57 |
COEPW Hedge Fund Activity: Q2 2026 in Review
3 of the 8,336 institutional investors tracked by Wall St. Rank reported a position in Coeptis Therapeutics Warrants (COEPW) for Q2 2026, worth a combined $2.73K — down 56% from $6.28K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of COEPW and 0 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Walleye Trading, exiting entirely with an estimated $927 sold.
- 3 institutional investors held Coeptis Therapeutics Warrants (COEPW) as of Q2 2026, down from 10 in Q1 2026.
- Funds reported $2.73K of Coeptis Therapeutics Warrants stock for Q2 2026, down 56% quarter-over-quarter.
- 0 funds opened new Coeptis Therapeutics Warrants positions in Q2 2026 and 7 closed out, a net change of -7 holders.
- The largest Coeptis Therapeutics Warrants seller in Q2 2026 was Walleye Trading, an estimated $927 sold.
Based on aggregated 13F filings for Q2 2026.